Venture Intelligence data shows that capital flowing into India's manufacturing startup sector climbed from $164 million in 2020 to $1.92 billion through 2026, reflecting a sustained expansion in investor appetite for the space. Deal volume climbed from 31 transactions recorded in 2020 to 127 by 2026.
Companies such as Pulse, a maker of medical equipment, and Scimplify, which manufactures specialty chemicals and operates an end-to-end supply chain platform, have been drawing growing orders from buyers within the domestic market. One industry participant noted that the disruptions of Covid led businesses to recognise the practical value of building redundancy into their supply arrangements.
Abhishek Srivastava, managing partner at early-stage venture capital firm Kae Capital, noted that those shifts opened up appetite for alternative global supply chains, with India taking shape as one viable option, while the expansion of the domestic market also led founders to recognise that companies could reach considerable scale before turning their attention to international growth. Among Kae Capital's portfolio positions in the manufacturing sector, Zetwerk — a business-to-business platform for manufactured goods that is working toward a public listing — stands out as one of the firm's earliest commitments in that space.
Heightened friction over tariffs and trade barriers has pushed companies toward spreading their sourcing across multiple regions while building out production capacity closer to home. Tariffs levied on goods flowing in from China marked the opening move in a trade dispute between the two economies that took hold in 2018. Reciprocal tariff measures rolled out in 2025 extended trade barriers to a broader range of partners — India among them — setting off a reassessment of global sourcing arrangements across many industries.
One speaker at the event pointed out that capital-intensive ventures had long struggled to attract investment, partly because repeated failures in that space left little residual worth to recover, and partly because the intangible value embedded in intellectual property went without meaningful recognition during that period. Worth, in that accounting, flowed exclusively toward those who held capital.
IP-led manufacturing stands out as a defining characteristic of the approach under examination. Proprietary intellectual property, an investor noted, stands as a prerequisite before any funding commitment can be made.
Vikas Choudhury, founder and managing partner of the growth-stage venture capital firm Playbook Partners, described the model as one that combines two distinct advantages within a single approach. Choudhury has argued that intellectual-property-centred production approaches can raise two distinct walls against competitors — one tied to the cost of capital, the other to technological know-how — with rivals potentially needing between one and two years to mount any meaningful response. Among the portfolio holdings of Playbook Partners sits Skyroot, a space technology venture that has attained unicorn status.
Two policy instruments — the production-linked incentive scheme and the electronics components manufacturing scheme — have formed the backbone of a government drive to expand domestic manufacturing capacity. Launched in 2020 to tie financial incentives to incremental output gains, the PLI scheme covers 14 industries — among them electronics, automobiles, and pharmaceuticals. Sumeet Seraf, founder and managing partner at the boutique investment banking platform Equity360, noted that rising investor appetite had positioned him to close as many as eight to ten manufacturing deals per quarter, up from the three or four he had been completing in earlier periods.
Orders flowing into Scimplify — a Bengaluru firm whose product range spans advanced materials, specialty chemicals, rare-earth oxides, and specialised metal compounds — have been climbing across sectors that include aerospace and defence, solar energy, semiconductors, batteries, and electric vehicles. Ministry of corporate affairs filings accessed via Tracxn put Scimplify's top-line figure at ₹204.3 crore for FY25, a result that compares with the ₹18.3 crore recorded in FY24 by a factor of roughly eleven. Its reported size has grown eightfold over that period, according to the company's own figures.
Beyond geopolitical considerations, the startup points to a decade of technological advancement within India as a driver of the growing demand it has recorded. At Technology Readiness Levels 4 and 5, a range of these technologies had cleared laboratory validation but remained some distance from deployment in commercial settings. A spokesperson noted that product categories tied to advanced materials work had expanded by more than tenfold across the preceding six months, while certain technologies in that field were now reaching the point where real-world performance had been verified and commercial rollout had become viable.
Revenue figures for the period show the organisation's income nearly doubled across a span of six months. Co-founder Sachin Santhosh projected that output would reach roughly twice the organisation's present volume within the following six months.
Founded roughly nine months before this report, Pulse supplies hospitals and clinics with a product range spanning low- to medium-complexity devices alongside their accompanying consumables, with coverage across critical care, renal care, cardiac care, aesthetics, and rehabilitation. The company partners with manufacturers and small and medium enterprises under contract manufacturing arrangements, while an R&D facility based in Visakhapatnam drives the development of its own designs and product lines. A spokesperson noted that, in proportional terms, the business volume recorded across the opening two months was relatively modest.
The organisation's size expanded to roughly eight times what it had been at that earlier point. Month-on-month expansion of between 30 and 40 percent has been recorded across consecutive reporting periods. Anshul Sharma, co-founder of Pulse, projected that the company's annualised revenue run rate would reach approximately ₹100 crore within the following one to two months. A Series A fundraising round is being pursued by the company, with proceeds earmarked for expanding research and development work and driving broader organisational growth.